Black Hawk Acquisition Corporation Units

Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement

Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles

Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board

Black Hawk Acquisition Corporation Announces Closing of $69,000,000 Initial Public Offering